Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
49.96
-1.10 (-2.15%)
At close: May 13, 2025, 4:00 PM
50.20
+0.24 (0.48%)
Pre-market: May 14, 2025, 8:31 AM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | NaN - NaN |
| Total Vaccine | 8.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Vaccine Growth | 12.87% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Pharmaceutical | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Pharmaceutical Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent | 13.72B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Dupixent Growth | 22.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Neurology & Immunology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Oncology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Rare Blood Disorders Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Non-Core Assets Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Industrial Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma | 42.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty Care | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharma | 33.62B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | NaN - NaN |
| Pharmaceutical Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Vaccine Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Consumer Healthcare Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income | 11.84B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Biopharma Operating Income Growth | 8.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Opella Consumer Healthcare (Post-2022 Reporting) Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income | 9.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other (Post-2022 Reporting) Operating Income Growth | 28.57% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | NaN - NaN |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | NaN - NaN |
| United States | 21.45B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 14.32% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 9.76B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | -5.17% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 13.43B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | -5.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|